The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider.
Ostarine, also known as MK-2866 or Enobosarm, is a selective androgen receptor modulator (SARM). It was initially developed to treat conditions such as muscle wasting and osteoporosis. However, it has gained popularity among athletes and bodybuilders for its potential to enhance muscle growth and improve physical performance.
Ostarine works by selectively binding to androgen receptors in the body, specifically in muscle and bone tissues. This binding activates the androgen receptors, leading to an increase in protein synthesis and the growth of muscle tissue. It also promotes the preservation of lean muscle mass while reducing muscle breakdown.
Unlike anabolic steroids, Ostarine has a selective action, meaning it primarily targets androgen receptors in muscle and bone tissues, while minimizing the potential side effects associated with traditional steroids. This selectivity is believed to contribute to its ability to promote muscle growth without causing significant androgenic or estrogenic side effects.
It is important to note that Ostarine is still under investigation and has not been approved by regulatory authorities for medical use. Its use in sports is considered doping and is prohibited by most athletic organizations. Additionally, the long-term effects and safety of Ostarine are still being studied, and potential risks and side effects are not yet fully understood.